EGFR and neoplasm: In the latter, WP1066 caused tumours to significantly regress over the treatment timecourse, accompanied by a reduction in infiltrating inflammatory cells, pro-inflammatory cytokines, Reg1, EGFR ligand amphiregulin expression, as well as oncogenic COX2.